This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Concert Pharmaceuticals Management

Management criteria checks 2/4

Key information

Roger Tung

Chief executive officer

US$3.5m

Total compensation

CEO salary percentage	17.0%
CEO tenure	16.9yrs
CEO ownership	1.4%
Management average tenure	4.3yrs
Board average tenure	16.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Roger Tung's remuneration changed compared to Concert Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2022	n/a	n/a	-US$127m
Jun 30 2022	n/a	n/a	-US$125m
Mar 31 2022	n/a	n/a	-US$95m
Dec 31 2021	US$4m	US$599k	-US$80m
Sep 30 2021	n/a	n/a	-US$66m
Jun 30 2021	n/a	n/a	-US$59m
Mar 31 2021	n/a	n/a	-US$77m
Dec 31 2020	US$3m	US$582k	-US$75m
Sep 30 2020	n/a	n/a	-US$73m
Jun 30 2020	n/a	n/a	-US$71m
Mar 31 2020	n/a	n/a	-US$77m
Dec 31 2019	US$3m	US$562k	-US$78m
Sep 30 2019	n/a	n/a	-US$79m
Jun 30 2019	n/a	n/a	-US$79m
Mar 31 2019	n/a	n/a	-US$73m
Dec 31 2018	US$5m	US$536k	-US$56m
Sep 30 2018	n/a	n/a	-US$41m
Jun 30 2018	n/a	n/a	US$104m
Mar 31 2018	n/a	n/a	US$104m
Dec 31 2017	US$3m	US$517k	US$95m
Sep 30 2017	n/a	n/a	US$89m
Jun 30 2017	n/a	n/a	-US$50m
Mar 31 2017	n/a	n/a	-US$50m
Dec 31 2016	US$3m	US$500k	-US$51m

Compensation vs Market: Roger's total compensation ($USD3.53M) is above average for companies of similar size in the German market ($USD867.99K).

Compensation vs Earnings: Roger's compensation has increased whilst the company is unprofitable.

CEO

Roger Tung (62 yo)

16.9yrs

Tenure

US$3,526,782

Compensation

Dr. Roger D. Tung, Ph D., Co-founded Concert Pharmaceuticals, Inc. in April 2006 and has been its Chief Executive Officer and President since April 2006. Dr. Tung worked in venture-backed start-up and majo...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Richard Aldrich	Co-Founder & Independent Chairman of the Board	16.8yrs	US$129.05k	0.89% $ 4.3m
Roger Tung	Co-Founder	16.9yrs	US$3.53m	1.37% $ 6.7m
Marc Becker	Chief Financial Officer	5.2yrs	US$1.38m	0.20% $ 970.3k
James Cassella	Chief Development Officer	8.1yrs	US$1.51m	0.13% $ 631.3k
Nancy Stuart	Chief Operating Officer	15.4yrs	US$1.58m	0.27% $ 1.3m
Justine Koenigsberg	Senior Vice President of Corporate Communications & Investor Relations	no data	no data	no data
Jeffrey Munsie	Chief Legal Officer & Corporate Secretary	3.5yrs	no data	0.062% $ 300.4k
Nabil Uddin	Vice President of Corporate Development	1.2yrs	no data	no data
Kimberly Mack	Vice President of Human Resources	less than a year	no data	no data
Christine Boisclair	Senior Vice President of Regulatory Affairs & Quality Assurance	1.2yrs	no data	no data

4.3yrs

Average Tenure

63yo

Average Age

Experienced Management: 73C's management team is considered experienced (4.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Richard Aldrich	Co-Founder & Independent Chairman of the Board	16.8yrs	US$129.05k	0.89% $ 4.3m
Roger Tung	Co-Founder	16.9yrs	US$3.53m	1.37% $ 6.7m
Christine van Heek	Independent Director	6.9yrs	US$99.05k	0.041% $ 200.9k
Peter Hutt	Independent Director	16.3yrs	US$94.05k	0.021% $ 102.5k
Wilfred Jaeger	Independent Director	16.8yrs	US$106.55k	0% $ 0
Jesper Hoiland	Independent Director	3.9yrs	US$96.55k	0.0082% $ 40.2k
Thomas Auchincloss	Independent Director	8.3yrs	US$109.05k	0.028% $ 138.1k

16.3yrs

Average Tenure

65yo

Average Age

Experienced Board: 73C's board of directors are seasoned and experienced ( 16.3 years average tenure).

This company listing is no longer active

Concert Pharmaceuticals Management

Management criteria checks 2/4

Key information

Recent management updates

Insufficient new directors

Insufficient new directors

Concert Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2022

Concert Pharmaceuticals, Inc. Announces Not Stand for Re-Election of Ronald W. Barrett as Independent Director

Recent updates

Concert Pharmaceuticals, Inc. Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata

Concert Pharmaceuticals Announces Presentation of Deuruxolitinib Thrive-Aa1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair Research

Insufficient new directors

Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.78 loss in 3Q 2021)

Concert Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Concert Pharmaceuticals Announces Presentation of CTP-543 THRIVE-AA1 Phase 3 Data in Alopecia Areata During Late Breaking Session at EADV Congress

Second quarter 2022 earnings released: US$0.59 loss per share (vs US$0.16 profit in 2Q 2021)

Concert Pharmaceuticals, Inc. Reports Positive Topline Results for Second CTP-543 Phase 3 Clinical Trial in Alopecia Areata

Concert Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Concert Pharmaceuticals, Inc.(NasdaqGM:CNCE) dropped from Russell Microcap Value Index

Concert Pharmaceuticals, Inc. Announces the Publication of Safety and Efficacy Data from the Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Phase 2 Clinical Trial for CTP-543

Concert Pharmaceuticals, Inc. Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata

First quarter 2022 earnings released: US$1.03 loss per share (vs US$0.67 loss in 1Q 2021)

Insufficient new directors

Concert Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Concert Pharmaceuticals, Inc. Announces Phase 3 Trials for Moderate to Severe Alopecia Areata

Concert Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Concert Pharmaceuticals, Inc. Announces Not Stand for Re-Election of Ronald W. Barrett as Independent Director

Concert Pharmaceuticals, Inc. Completes Enrollment in THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

Third quarter 2021 earnings released: US$0.78 loss per share (vs US$0.60 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS US$0.16 (vs US$0.41 loss in 2Q 2020)

Concert Pharmaceuticals Presents Update on CTP-543 Long-Term Extension Study in Alopecia Areata During 2nd JAK Inhibitors Drug Development Summit

Concert Pharmaceuticals, Inc.(NasdaqGM:CNCE) dropped from Russell 3000E Value Index

Concert Pharmaceuticals Initiates THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

First quarter 2021 earnings released: US$0.67 loss per share (vs US$0.70 loss in 1Q 2020)

Concert Pharmaceuticals Reports CTP-543 Phase 3 Program for Alopecia Areata Advancing as Planned to Support NDA Filing in Early 2023

Full year 2020 earnings released: US$2.40 loss per share (vs US$3.29 loss in FY 2019)

Revenue beats expectations

Concert Pharmaceuticals, Inc. Provides Update on Clinical Programs

New 90-day low: €5.70

Concert Pharmaceuticals, Inc. to Report Fiscal Year 2020 Results on Feb 25, 2021

Concert Pharmaceuticals, Inc. Announces Results from CTP-692 Phase 2 Trial in Patients with Schizophrenia

New 90-day low: €5.75

New 90-day high: €10.60

Third quarter 2020 earnings released: US$0.60 loss per share

Revenue in line with expectations

Concert Pharmaceuticals Initiates THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

Concert Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day high: €10.20

New 90-day high: €9.65

Concert Pharmaceuticals, Inc. Completes CTP-692 Phase 2 Trial Enrollment in Patients with Schizophrenia

First half earnings released

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age